The regulatory scrutiny centers on a May 2026 FDA warning letter, which identified critical failures in the company's manufacturing processes. Federal inspectors cited Medline for inadequate investigation into microbial contamination incidents and poor cleaning practices. This warning marked the second regulatory action against the firm within a two-month window, contributing to a 7% share price decline immediately following the public disclosure of the FDA’s findings.
Investor sentiment soured further on August 5, 2026, when the company reported its second-quarter results and simultaneously lowered its full-year adjusted EBITDA guidance. Kessler Topaz Meltzer & Check, LLP is now soliciting information from Class A common stock holders to determine if the company’s disclosures misled the market. Attorney Jonathan Naji is overseeing the inquiry, which remains open to investors seeking to discuss their legal standing regarding these losses.
Comments (0)
No comments yet. Be the first!